Mar 21 2025
Hemophilia Therapeutics Discontinued
Thank you to Elaine Benoit, Precision BioLogic Inc, for this heads-up. Today, 22 March 2025, Takeda Pharmaceuticals U.S.A., Inc announced it has discontinued the production of therapeutics HEMOFIL M® and RECOMBINATE®, both among the first of the synthetic FVIII concentrates. The factors, which required the use of sterile human serum albumin in their manufacture, remain […]
read more